|
'''BRL-50481''' is a drug developed by ] which is the first compound that acts as a ] selective for the ] family.<ref>{{cite journal | vauthors = Smith SJ, Cieslinski LB, Newton R, Donnelly LE, Fenwick PS, Nicholson AG, Barnes PJ, Barnette MS, Giembycz MA | display-authors = 6 | title = Discovery of BRL 50481 , a selective inhibitor of phosphodiesterase 7: in vitro studies in human monocytes, lung macrophages, and CD8+ T-lymphocytes | journal = Molecular Pharmacology | volume = 66 | issue = 6 | pages = 1679–89 | date = December 2004 | pmid = 15371556 | doi = 10.1124/mol.104.002246 | s2cid = 9491524 | url = http://molpharm.aspetjournals.org/content/molpharm/66/6/1679.full.pdf }}</ref> PDE7 activity is encoded by two genes, ] and ]. BRL-50481 actually shows about an 80-fold preference for the PDE7A subtype, for which it was developed, over PDE7B.<ref>{{cite journal | vauthors = Alaamery MA, Wyman AR, Ivey FD, Allain C, Demirbas D, Wang L, Ceyhan O, Hoffman CS | display-authors = 6 | title = New classes of PDE7 inhibitors identified by a fission yeast-based HTS | journal = Journal of Biomolecular Screening | volume = 15 | issue = 4 | pages = 359–67 | date = April 2010 | pmid = 20228279 | pmc = 2854023 | doi = 10.1177/1087057110362100 }}</ref> BRL-50481 has been shown to increase mineralisation activity in ]s, suggesting a potential role for ]s in the treatment of ].<ref>{{cite journal | vauthors = Pekkinen M, Ahlström ME, Riehle U, Huttunen MM, Lamberg-Allardt CJ | title = Effects of phosphodiesterase 7 inhibition by RNA interference on the gene expression and differentiation of human mesenchymal stem cell-derived osteoblasts | journal = Bone | volume = 43 | issue = 1 | pages = 84–91 | date = July 2008 | pmid = 18420479 | doi = 10.1016/j.bone.2008.02.021 }}</ref> |
|
'''BRL-50481''' is a drug developed by ] which is the first compound that acts as a ] selective for the ] family.<ref>{{cite journal | vauthors = Smith SJ, Cieslinski LB, Newton R, Donnelly LE, Fenwick PS, Nicholson AG, Barnes PJ, Barnette MS, Giembycz MA | display-authors = 6 | title = Discovery of BRL 50481 , a selective inhibitor of phosphodiesterase 7: in vitro studies in human monocytes, lung macrophages, and CD8+ T-lymphocytes | journal = Molecular Pharmacology | volume = 66 | issue = 6 | pages = 1679–89 | date = December 2004 | pmid = 15371556 | doi = 10.1124/mol.104.002246 | s2cid = 9491524 | url = http://molpharm.aspetjournals.org/content/molpharm/66/6/1679.full.pdf }}</ref> PDE7 activity is encoded by two genes, ] and ]. BRL-50481 actually shows about an 80-fold preference for the ] subtype, for which it was developed, over ].<ref>{{cite journal | vauthors = Alaamery MA, Wyman AR, Ivey FD, Allain C, Demirbas D, Wang L, Ceyhan O, Hoffman CS | display-authors = 6 | title = New classes of PDE7 inhibitors identified by a fission yeast-based HTS | journal = Journal of Biomolecular Screening | volume = 15 | issue = 4 | pages = 359–67 | date = April 2010 | pmid = 20228279 | pmc = 2854023 | doi = 10.1177/1087057110362100 }}</ref> BRL-50481 has been shown to increase mineralisation activity in ]s, suggesting a potential role for ]s in the treatment of ].<ref>{{cite journal | vauthors = Pekkinen M, Ahlström ME, Riehle U, Huttunen MM, Lamberg-Allardt CJ | title = Effects of phosphodiesterase 7 inhibition by RNA interference on the gene expression and differentiation of human mesenchymal stem cell-derived osteoblasts | journal = Bone | volume = 43 | issue = 1 | pages = 84–91 | date = July 2008 | pmid = 18420479 | doi = 10.1016/j.bone.2008.02.021 }}</ref> |
